BridgeBio Pharma shares are trading higher in reaction to Alnylam Pharmaceuticals' detailed data from HELIOS-B Phase 3 study of vutrisiran. BridgeBio Pharma has ATTR-CM therapy acoramidis, currently under FDA priority review with an action date of November 29.
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma shares rise following Alnylam Pharmaceuticals' positive data from the HELIOS-B Phase 3 study of vutrisiran. BridgeBio's ATTR-CM therapy, acoramidis, is under FDA priority review with a decision expected by November 29.
August 30, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BridgeBio Pharma shares are trading higher due to positive data from Alnylam's HELIOS-B study, which may positively influence perceptions of BridgeBio's own ATTR-CM therapy, acoramidis, currently under FDA review.
The positive data from Alnylam's study may boost investor confidence in similar therapies, including BridgeBio's acoramidis. The upcoming FDA decision adds to the stock's potential volatility.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80